Anthony S. Fauci
In a collaborative effort between the National Institute of Allergy and Infectious Diseases at the NIH and the Children’s National Health System in Washington D.C., the institutions established a partnership to promote research on pediatric allergic, infectious, autoinflammatory and immunologic disease. The partnership, established in 2017, met today at a symposium highlighting their current and upcoming research.
Those attending this symposium will be able to ask questions regarding the research and suggest areas of research where more information is needed.
“Collaborating with a renowned pediatric hospital in our community promises to advance clinical research efforts, ensure the best possible care for children participating in research studies and aid the development of medical innovations to improve the lives of children worldwide,” Anthony S. Fauci, MD, NIAID director, said in a press release. “The partnership also expands and enhances the ability of both institutions to provide medical and research training opportunities for the next generation of clinicians and scientists specializing in pediatric allergy, immunology and infectious diseases.”
The studies conducted by the partnership examine the prevention, diagnosis, treatment and curability of diseases affecting the immune system. Clinical trials will be held at both the Children’s National Health System and the NIH.
In addition to conducting research for these pediatric conditions, this partnership provides the opportunity to train physician-scientists in both the care of these children and refine their knowledge of these conditions.
“This collaboration between an NIH institute and a specialized pediatric medical center ensures that the youngest research participants receive the gold standard of medical care,” James K. Gilman, MD, CEO of the NIH Clinical Center, said in the release. “My hope is that this partnership between NIAID and Children’s National, focused on allergic, immunologic and infectious diseases, will serve as a model for future collaborations to address additional diseases and health conditions.” – by Katherine Bortz